Eli Lilly and Company $LLY Shares Sold by Private Wealth Asset Management LLC

Private Wealth Asset Management LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,457 shares of the company’s stock after selling 524 shares during the quarter. Eli Lilly and Company accounts for 0.9% of Private Wealth Asset Management LLC’s investment portfolio, making the stock its 21st biggest holding. Private Wealth Asset Management LLC’s holdings in Eli Lilly and Company were worth $7,979,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of LLY. Laurel Wealth Advisors LLC increased its position in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank purchased a new position in Eli Lilly and Company in the second quarter valued at about $8,827,714,000. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after acquiring an additional 1,183,038 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Eli Lilly and Company by 13.4% during the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its holdings in Eli Lilly and Company by 87.2% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock worth $898,238,000 after buying an additional 536,679 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Signed a potential $1.93 billion deal with Repertoire to develop autoimmune therapies — expands Lilly’s immune‑disease pipeline and adds milestone/licensing upside that could underpin future revenue growth and valuation. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Positive Sentiment: Entered a deal (up to ~$1.12B) with Seamless Therapeutics to develop gene‑editing treatments for hearing loss — adds high‑value, high‑optionality programs and gives Lilly exposure to novel recombinase technology. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: Oncology and AI catalysts: coverage highlights Lilly’s oncology pipeline plus a ~$1B AI collaboration with Nvidia to speed drug discovery — could accelerate new launches and support mid‑term revenue growth. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Positive Sentiment: Analyst/earnings setup looks favorable: earnings‑surprise history and consensus expectations point to another likely beat, supporting near‑term sentiment around fundamentals. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Positive investor writeups and “top picks” pieces argue for multi‑year growth driven by GLP‑1 leadership and pipeline, but these are opinion pieces that may already be priced in. Top Picks 2026: Eli Lilly & Co.
• Negative Sentiment: Medicare drug price negotiation named a Lilly Part B product (Verzenio) for talks — introduces downside risk to pricing and margins if negotiated cuts apply to key products. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Competitive pressure: Reuters data shows Novo Nordisk doubled U.S. ad spend vs. Lilly for GLP‑1s — implies intensified market share battle and potentially higher marketing costs or share erosion. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Market reaction note: coverage points out shares fell even after the gene‑editing tie‑ups, signaling investor concerns about valuation, near‑term growth execution, or policy/competitive risks despite the deals. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Analyst Ratings Changes

Several brokerages have weighed in on LLY. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Wolfe Research raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Zacks Research raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Finally, Berenberg Bank increased their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $1,173.91.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,024.14 on Thursday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The stock has a market cap of $968.20 billion, a PE ratio of 50.10, a PEG ratio of 0.79 and a beta of 0.35. The firm’s 50 day moving average price is $1,057.65 and its two-hundred day moving average price is $886.06. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.